Medexus Pharmaceuticals Inc. (MDP.TO)
CAD 2.76
(-1.43%)
CAD 2.76
(-1.43%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 113.05 Million USD | 4.59% |
| 2022 | 108.09 Million USD | 40.93% |
| 2021 | 76.7 Million USD | -3.71% |
| 2020 | 79.66 Million USD | 51.93% |
| 2019 | 52.43 Million CAD | 106.73% |
| 2018 | 25.36 Million CAD | 227.23% |
| 2017 | 7.75 Million CAD | 66.52% |
| 2016 | 4.65 Million CAD | 61.1% |
| 2015 | 2.88 Million CAD | -21.76% |
| 2014 | 3.69 Million CAD | 20.34% |
| 2013 | 3.06 Million CAD | 0.0% |
| 2012 | - CAD | 0.0% |
| 2011 | - CAD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 27.28 Million USD | 5.09% |
| 2023 Q4 | 25.96 Million USD | 2.98% |
| 2023 Q3 | 25.21 Million USD | -16.87% |
| 2023 Q2 | 30.32 Million USD | -3.89% |
| 2023 Q1 | 31.55 Million USD | 10.21% |
| 2023 FY | 113.05 Million USD | 4.59% |
| 2022 Q1 | 23.04 Million USD | 13.73% |
| 2022 Q2 | 27.68 Million USD | 20.13% |
| 2022 Q3 | 28.73 Million USD | 3.77% |
| 2022 Q4 | 28.63 Million USD | -0.34% |
| 2022 FY | 108.09 Million USD | 40.93% |
| 2021 FY | 76.7 Million USD | -3.71% |
| 2021 Q2 | 17.9 Million USD | 3.67% |
| 2021 Q3 | 21.27 Million USD | 18.82% |
| 2021 Q1 | 17.26 Million USD | 16.38% |
| 2021 Q4 | 20.26 Million USD | -4.73% |
| 2020 Q3 | 24.71 Million CAD | 39.98% |
| 2020 Q4 | 14.83 Million USD | -39.96% |
| 2020 Q2 | 17.65 Million CAD | -12.37% |
| 2020 Q1 | 20.14 Million CAD | 33.17% |
| 2020 FY | 79.66 Million USD | 51.93% |
| 2019 Q1 | 12.28 Million CAD | 24.63% |
| 2019 Q3 | 12.4 Million CAD | 0.15% |
| 2019 Q2 | 12.38 Million CAD | 0.83% |
| 2019 FY | 52.43 Million CAD | 106.73% |
| 2019 Q4 | 15.12 Million CAD | 21.96% |
| 2018 Q1 | 2.47 Million CAD | 68.78% |
| 2018 Q4 | 9.85 Million CAD | -6.91% |
| 2018 FY | 25.36 Million CAD | 227.23% |
| 2018 Q3 | 10.58 Million CAD | 296.61% |
| 2018 Q2 | 2.66 Million CAD | 8.06% |
| 2017 Q1 | 1.89 Million CAD | 49.21% |
| 2017 Q3 | 1.87 Million CAD | -24.6% |
| 2017 Q4 | 1.46 Million CAD | -21.9% |
| 2017 FY | 7.75 Million CAD | 66.52% |
| 2017 Q2 | 2.48 Million CAD | 31.11% |
| 2016 Q2 | 1.43 Million CAD | 107.37% |
| 2016 FY | 4.65 Million CAD | 61.1% |
| 2016 Q1 | 690.34 Thousand CAD | 5.35% |
| 2016 Q4 | 1.27 Million CAD | -3.68% |
| 2016 Q3 | 1.31 Million CAD | -7.85% |
| 2015 FY | 2.88 Million CAD | -21.76% |
| 2015 Q4 | 655.28 Thousand CAD | -11.07% |
| 2015 Q3 | 736.86 Thousand CAD | -32.78% |
| 2015 Q2 | 1.09 Million CAD | 124.69% |
| 2015 Q1 | 487.9 Thousand CAD | -63.72% |
| 2014 Q1 | 829.75 Thousand CAD | 0.0% |
| 2014 FY | 3.69 Million CAD | 20.34% |
| 2014 Q4 | 1.34 Million CAD | 69.99% |
| 2014 Q2 | 831.63 Thousand CAD | 0.23% |
| 2014 Q3 | 791.23 Thousand CAD | -4.86% |
| 2013 Q3 | 1.16 Million CAD | 0.0% |
| 2013 FY | 3.06 Million CAD | 0.0% |
| 2013 Q1 | - CAD | 0.0% |
| 2013 Q2 | - CAD | 0.0% |
| 2012 Q4 | - CAD | -100.0% |
| 2012 Q1 | - CAD | 0.0% |
| 2012 Q3 | 573.91 Thousand CAD | 0.0% |
| 2012 FY | - CAD | 0.0% |
| 2012 Q2 | - CAD | 0.0% |
| 2011 Q4 | - CAD | 0.0% |
| 2011 FY | - CAD | 0.0% |
| 2011 Q2 | - CAD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Aurora Cannabis Inc. | 270.28 Million CAD | 58.172% |
| Avicanna Inc. | 16.79 Million CAD | -573.282% |
| Avant Brands Inc. | 26.34 Million CAD | -329.145% |
| Cardiol Therapeutics Inc. | - CAD | -Infinity% |
| Crescita Therapeutics Inc. | 17.52 Million CAD | -545.212% |
| Knight Therapeutics Inc. | 328.19 Million CAD | 65.553% |
| MediPharm Labs Corp. | 33.06 Million CAD | -241.945% |
| OrganiGram Holdings Inc. | 149.2 Million CAD | 24.229% |
| Canopy Growth Corporation | 297.14 Million CAD | 61.953% |
| Willow Biosciences Inc. | 1.17 Million CAD | -9546.246% |
| Auxly Cannabis Group Inc. | 101.07 Million CAD | -11.848% |